An intracranial mouse glioma model was used to study the effectiveness of chemotherapy with methotrexate (MTX) or radiotherapy. Maximum tolerable doses of MTX were established by toxicity studies in nontumor-bearing mice for the intraperitoneal and intracerebral routes of drug administration with and without leucovorin as an antidote. These maximum tolerable doses were then given either by the intraperitoneal route or directly into the tumor to mice bearing intracerebral tumors. The glioma model proved to be extremely useful for assessing the modalities studied, including repeated intraneoplastic injection of MTX. Dosage schedules were successfully developed for administering large amounts of MTX and for preventing systemic toxicity by the administration of the antidote. Radiotherapy in single doses of 800 rads delayed the median day ofdeath and produced several long-term survivors. Higher doses were toxic. Intraperitoneal or intraneoplastic MTX was completely ineffective as a chemotherapeutic agent for this tumor, even though very large amounts could be delivered due to the protection from systemic toxicity afforded by leucovorin. It is concluded that MTX is a poor chemotherapeutic agent for this experimental brain tumor, but that the technique of intraneoplastic administration of chemotherapeutic agents is feasible with this model system and should be studied further.
that are proliferating and in S-phase, and these constitute only a fraction of the cells present in brain tumors at a given time. 17,'s,5' Many types of neoplastic cells have been found to be resistant to MTX either because of induction of the enzyme dihydrofolate reductase to which MTX binds, 5,6,~7 or because the neoplastic cells are impermeable to the drug. ~,13,19,~2,51-5s, 57 It is of major importance that MTX is an ionized, watersoluble compound and does not achieve high concentrations in normal brain. 46 Since MTX has been one of the most frequently used agents for brain-tumor chemotherapy in patients 9,~4,26,28-s~,sS,37,4~176 it was decided to study its chemotherapeutic potential in an intracerebral mouse glioma model recently developed in our laboratory. 4~ This model affords the opportunity of studying the effect of MTX given either parenterally or by direct intraneoplastic injection. For purposes of comparison, the effect of radiotherapy on this intracerebral tumor model was also studied.
Materials and Methods

Materials
We used C57BL/6J female mice* weighing 16 to 18 gm. A mouse ependymoblastoma obtained in 1963 and maintained in our laboratory since then by serial subcutaneous transplantation every 2 weeks was used. The tumor was originally induced by Zimmerman and Arnold e~ in mouse brain with intracerebrally implanted methylcholanthrene. Methotrexatet was dissolved in sterile distilled H20 with pH adjusted to 8.4 with 1% NaOH immediately before injection.
Tumor Cell Suspension and Intracerebral Implantation
A suspension of neoplastic cells was made from a sufficient number of mice bearing 2-week-old subcutaneous ependymoblastomas to yield 2 gm of tumor tissue. The tumor was then trypsinized in Ca-Mg-free phosphatebuffered saline to produce a suspension of tumor cells containing 100,000 cells//~l as previously described. 49 After the addition of *The mice were obtained from the Jackson Laboratory, Bar Harbor, Maine.
tMethotrexate and leucovorin were kindly donated by American Cyanamid of Canada, Montreal, Canada.
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penicillin and streptomycin, 3 #1 of the tumor cell suspension was injected into the right frontal region of the brain by means of a No. 30 needle attached to a micrometer syringe assembly in a specially designed stereotaxic frame. 49 
Radiotherapy
Radiotherapy was administered to the whole head with the mice anesthetized with phentobarbital administered intraperitoneally and placed in a shielded box so that only the head was irradiated. Irradiation was carried out with a Picker Industrial Gemini 160/320 x-ray machine set at 10 mA and 100 kV to deliver 18 rads/sec. Doses of 400, 800, 1200, and 1600 rads were given to four groups of 15 mice each on the fifth day after intracerebral tumor implantation. A control group of 15 mice received no radiotherapy.
Methotrexate Toxicity Studies
The purpose of the toxicity studies was to establish the maximum tolerable doses to MTX that might be administered, usually the LD~o, when the drug was given intraperitoneally or intracranially to normal mice with or without leucovorin.
Intraperitoneal Methotrexate
Intraperitoneal MTX was administered every half hour for eight injections. The volume injected each time was 0.1 ml solution through a No. 30 needle with the dose of MTX ranging between 0.15 and 9.6 mg/kg. Ten control animals received the sterile distilled water diluent without MTX.
Intracerebral Methotrexate
The tolerance of mice to repeated intracerebral injections of diluent or MTX was studied with and without leucovorin. The injections were given through a No. 30 needle attached to the micrometer-syringe assembly with the mice in the stereotaxic frame noted above. Ten control mice received diluent every half hour for eight injections each day for up to 3 days, and the MTX groups received 0.3 to 1.2 mg/kg of MTX for up to 3 days.
In order to give higher doses of intracerebral MTX, an attempt was made to prevent the systemic toxicity of MTX by administering leucovorin in doses ranging from 2.4 to 4.8 mg/kg. The dose of MTX was 2.4 mg/kg given intracerebrally as a single daily injection for 5 to 15 days, then the leucovorin was administered intraperitoneally through a No. 23 needle in 0.05 ml saline 15 minutes after the MTX injection. Leucovorin therapy commenced on the same day that MTX was begun, and continued for 10 days after the termination of MTX therapy 9 t/1 t~ tD
Methotrexate Chemotherapy Studies
The chemotherapeutic experiments were cperformed with the maximum tolerable doses of MTX as determined from the toxicity ~. studies. Treatment commenced on the fifth day after intracerebral tumor implantation. The groups consisted of 15 to 30 tumor-= bearing mice. Two types of control groups E= were used to assess any positive or negative influences on survival due to the effect of the intraperitoneal or intraneoplastic injection procedures themselves 9 Control-1 animals received intracerebral tumor implants, but no other injections were given. Control-2 animals received intracerebral tumor implants and then intraneoplastic injections of diluent.
Analysis of Data from Therapeutic Studies
The median day of death was determined graphically for the therapeutic studies as in Fig. 1 . In the radiotherapy studies, comparison was made between median day of death for irradiated and non-irradiated control groups. In the chemotherapy experiments, comparison was made between the median day of death of treated and control-2 animals and the percentage increase or decrease in life-span was thus determined. Long-term survivors were defined as animals living more than 60 days from the time of tumor implantation. Significant prolongation (therapeutic) or shortening (toxic) of survival was assessed by the Kolmogorov-Smirnov test as adapted by Tate and Clelland. 43 To test the significance of differences between proportions as in the evaluation of the number of long-term survivors, a table prepared by Csima and Reid 8 based on Fisher's exact procedure was used. cumulative death rate plotted against time. Shift of the curve to the left of the control curve indicates toxicity and shift to the right indicates a positive therapeutic effect. Thus 1200 and 1600 rads produced toxicity as indicated by a more rapid rate of death (p < 0.01). The 800-rad group showed a positive therapeutic effect (p < 0.01) and the 400-rad group showed neither toxicity nor improved survival as compared with the controls. There were four long-term survivors in the 800-rad group and none in the other four groups (Table 1) .
Results
Radiotherapy Studies
Methotrexate Toxicity Studies
Intraperitoneal Methrotrexate. In all the intraperitoneal MTX toxicity studies the drug was given every half hour for eight injections at varying individual doses for a variable *Significance as compared with the control group. NS = not significant; significance = p < 0.01; Rx = significant positive therapeutic value; Tox = significant toxicity causing reduction in life-span.
number of days. It may be seen from Table 2 that the control mice tolerated this injection schedule for at least 7 days with no deaths. With individual intraperitoneal doses of MTX of 0.3 mg/kg there were no deaths when the drug was given for 1 or 2 days; however, there was a progressive increase in the number of deaths when the drug was given for 3 or more days, with almost all the mice dying when the drug was given for 5 to 7 days. At either 0.6 or 1.2 mg/kg the drug was tolerated for only 1 day of injection, and at higher doses, an increasing number of deaths were observed (Table 2) .
Intracerebral Methotrexate. The mice were able to tolerate repeated intracerebral injections of diluent at a frequency of every half hour for eight injections for up to 3 days without any deaths (Table 3 ). The mice receiving intracerebral injections of MTX were able to tolerate 0.3 mg/kg MTX for up to 3 days with no deaths, but with doses of 1.2 mg/kg, toxicity increased markedly after 1 day (Table 3) . At this dose level there were infrequent convulsions after intracerebral injections but no deaths due to convulsions.
There was only one death when a daily dose of 2.4 mg/kg of MTX without leucovorin was given for 5 days, but when given for 10 days, nine of 10 animals died, and for 15 days, all 10 died (Table 3) . Leucovorin effectively prevented this toxicity when it was continued for 10 days after cessation of MTX. With a daily dose of 2.4 mg/kg of MTX there were frequent convulsions, but only one death attributable to this factor. An attempt was made to give 4.8 mg/kg intracerebrally but this produced convulsions in all mice and death resulted in about half. Table 4 lists the results of the chemotherapy studies with intraperitoneal or intraneoplastic MTX. In the intraperitoneal studies no chemotherapeutic value was demonstrated in any of the dosage schedules employed, although these were the maximum tolerable doses as indicated by the toxicity studies. The intraperitoneal studies with MTX and leucovorin ( Fig. 2 and Table 4) showed that there was no chemotherapeutic value to this regimen, although leucovorin was successful in preventing the systemic toxicity of MTX.
Methotrexate Chemotherapy Studies.
Intraneoplastic MTX was completely ineffective in prolonging the survival of mice with brain tumors (Fig. 2 and Table 4 ) even though maximum doses were used. Similarly, increasing the dose of intraneoplastic MTX by preventing the systemic toxicity with intraperitoneal leucovorin did not prolong survival even though the dosage schedule successfully prevented toxicity.
Discussion
Much of the data upon which the present experiments were based came from our previous studies of the uptake and distribution of tritiated methotrexate as shown by autoradiography and liquid scintillation counting. [44] [45] [46] [47] In those studies we characterized the uptake and distribution from the intraperitoneal and intraneoplastic routes of a dose of MTX of 0.3 mg/kg which is of the same order of magnitude as doses of MTX given to patients. We observed that single intraperitoneal or intraneoplastic doses generally failed to penetrate into all areas of intracerebral growths of the mouse ependymoblastoma and that there was a rapid absorption into the blood stream of intracerebral MTX.
It 1.2 to 8 weeks, 2~ to 57 hours, TM with the latter be-2.4 ing much more likely. The S-phase has been 4.8 estimated to range from 7 to 10 hours? 7 A 9.6 tumor must be exposed to an S-phase specific drug for at least one complete cell-generation time because cell division occurs asynchron- *In each case eight injections per day were given, one every half hour, for the number of days indicated.
tControl animals received diluents, but no MTX. tql/2h X 8 = eight injections given per day, one every half hour, for the number of days indicated. ~LV = leucovorin. The teucovorin or diluent was administered intraperitoneally in each instance. w as compared with the appropriate control group in each series. NS = not significant, toxic = significant toxicity causing reduction in life-span.
ously among its cells. The schedule of halfhourly injections for 4 hours would cover only a portion of the cell-cycle time if given for only 1 day, but the MTX that persists would extend the period of coverage considerably, as proven by our previous autoradiographic and counting data that showed that some MTX persists for days after intraperitoneal or intraneoplastic injection? 8, 47 The schedules that extended more than 1 day would ensure exposure for longer periods. In addition, it is likely that the generation time in the mouse glioma is much shorter than in the human gliomas.
The toxicity studies successfully established dosage schedules for the frequent administration of high doses of MTX for the maximally permissible number of days. A dosage regimen of MTX, and leucovorin to protect against the systemic toxicity of MTX, was accomplished for both intraperitoneal and intracerebral administration of MTX. There was remarkable similarity between the systemic toxicity of intraperitoneal and intracerebral MTX (Tables 2 and 3 ). This is probably due to the rapid absorption of unchanged, non-metabolized MTX into the blood stream after intracerebral injection, reflecting our previous finding that only a fraction is retained in the head after intracerebral injection? 7
The intracerebral glioma model proved to be excellent for studying brain-tumor chemotherapy and radiotherapy. The model is easy to use and provides data that are readily interpretable. Toxic or positive therapeutic results are clearly discernible (Figs. 1 and 2 ) and can be analyzed statistically. This was best demonstrated in the radiotherapy study where radiotoxicity and radiotherapeutic effectiveness were both present in the same experiment ( Fig. 1 and Table 1 ). Another advantage of this model system is its applicability to the study of chemotherapeutic agents administered directly into brain tumors. Table 3 shows that the control normal mice tolerated repeated intracerebral injections of diluent with no deaths even when the injections were made every half hour for 8 injections daily for as long as 3 days. In some of the experiments in Table 4 , two types of control groups were used to assess the effects of repeated injections into the intracranial tumors. The results show that repeated intraneoplastic injections neither hastened death by the repeated trauma of the injections nor improved survival by any mechanical disruption of the tumors. It proved to be impossible to inject higher doses of MTX into the tumor because of the occurrence of convulsions. The cause of these are not known, but may be related to the preservatives in the commercial preparation of MTX. Convulsions have also been reported in dogs after intrathecal MTX, a3 and in patients given MTX for meningeal leukemia; ',','~ however, with moderate doses, intrathecal MTX is tolerated well by patients. 1~ With the doses of intraneoplastic MTX listed in Table 4 , except 2.4 mg/kg, convulsions were rare.
It is unlikely that prolongation of the interval between intraneoplastic or intraperitoneal MTX and intraperitoneal injection of leucovorin would have improved responsiveness, and indeed prolongation may have increased systemic toxicity. In patients with meningeal leukemia receiving intrathecal MTX leucovorin has been injected after an interval of 10 to 15 minutes, s3 although intervals as long as 24 to 36 hours have been used in some series when both drugs have been administered systemically? 8 Excellent results were achieved with simultaneous injections of MTX intrathecally and leucovorin intramuscularly for the treatment of meningeal involvement in patients with Burkitt's lymphoma? ~
The failure of MTX to exert a chemotherapeutic effect on this experimental glioma is probably not due to the failure of the agent to reach the tumor cells in high enough con- There was marked toxicity in the group with intraneoplastic MTX plus intraperitoneal diluent, with many early deaths and a median day of death of only 9 days. Although the intraneoplastic MTX group with intraperitoneal leucovorin showed an early accelerated death rate, after 25 days the death rate was similar to the control-2 group with intraneoplastic diluent plus intraperitoneal diluent, indicating the successful protection of leucovorin against MTX toxicity. The graphs show the failure of intraneoplastic or intraperitoneal MTX to improve survival.
centration. Resistance to MTX has been found with many other neoplastic or normal cells, and is thought to be due to either induction of the enzyme dihydrofolate reductase to which MTX binds, 5,6,27 or to failure of the drug to be transported into the neoplastic cells.12,13,19,22,51 53.57 It is not known if enzyme induction occurred in the present experiments or if enzyme induction prevented MTX from exerting a chemotherapeutic response in the glioma-bearing mice. It is interesting to note that certain tumors such as osteogenic sarcomas, which have not responded to conventional doses of MTX, have recently been shown to respond to massive doses of MTX with leucovorin rescue. 7 Thus, it is possible, although extremely unlikely, that even higher doses than used in the present experiment might exert a therapeutic effect. Higher doses could not be achieved by the intracerebral route because of convulsions, but might be possible by a combination of intraperitoneal and intracerebral routes, combined with leucovorin. Other ways of increasing the effectiveness of MTX which might have been tried include premedication with vincristine to increase the effective concentration of MTX in tumor cells, 8,58 combination chemotherapy with adriamycin, or "rescue" with thymidine. 7
Methotrexate has been used frequently for brain-tumor chemotherapy experimentally 38,'1,5e and clinically, 25,2~-31'35'37''~ and the results have generally been poor. The results have been somewhat better with intrathecal MTX than with intraperitoneal or intravenous MTX? 6 Of major significance is the recent report by Garfield and Dayan 9 who injected MTX daily through an indwelling catheter directly into malignant brain tumors in eight patients with gliomas and one with metastatic adenocarcinoma and found no demonstrable benefit. Together with the findings in the present study, the results suggest that glial tumors in general may be quite resistant to this drug.
Although intraneoplastic MTX has been found to be without value in the present study, we believe that further laboratory animal study of direct intraneoplastic injections of chemotherapeutic agents is warranted. Direct injection of MTX, 9'14,3~176 cyclophosphamide, ~5,a4 and thio-TEPA 2e has been studied in patients with brain tumors, but there have not been any previous reports of this approach in animals with brain tumor. The present study indicates the feasibility of the experimental study of this approach using systemically injected antidote.
